A5043867966- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Cancer-related cognitive impairment studies
- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Genital Health and Disease
- Urologic and reproductive health conditions
- Colorectal Cancer Treatments and Studies
- Advances in Oncology and Radiotherapy
- Hormonal and reproductive studies
- Global Cancer Incidence and Screening
- Statistical Methods in Clinical Trials
- Pancreatic and Hepatic Oncology Research
- Radiation Dose and Imaging
- Cancer, Lipids, and Metabolism
University Health Network
2018-2024
University of Toronto
2021-2024
Princess Margaret Cancer Centre
2018-2024
Abstract Background Grade Group 1 (GG1) prostate cancer should be managed with active surveillance (AS). Global uptake of AS remains disappointingly slow and heterogeneous. Removal labels has been proposed to reduce GG1 overtreatment. We sought determine the impact disease terminology on individual’s perceptions decision making. Methods Discrete choice experiments were conducted 3 cohorts: healthy men, canonical partners (partners), patients (patients). Participants reported preferences in a...
PurposeBrain metastases (BrM) are common in patients with epidermal growth factor receptor (EGFRm) mutant non-small cell lung cancer (NSCLC). We sought to determine the rate of neurologic death (ND) this population.Methods and MaterialsWe analyzed data from 198 who received a diagnosis BrM EGFRm NSCLC between 2004 2016, comparing whose initial treatment for was stereotactic radiosurgery or without tyrosine kinase inhibitors (TKI), whole brain radiation therapy (WBRT) TKI, TKI alone. The...
You have accessJournal of UrologyCME1 Apr 2023MP29-03 MULTI-INSTITUTIONAL ANALYSIS OF METASTASIS DIRECTED THERAPY WITH OR WITHOUT ANDROGEN DEPRIVATION IN OLIGOMETASTATIC CASTRATION SENSITIVE PROSTATE CANCER Matthew Deek, Phillip Sutera, Yuezhou Jing, David Pryor, Heather Day, Mai Anh Huynh, Bridget Koontz, Andrew Armstrong, Ellen Debruycker, Piet Dirix, Carole Mercier, Ost, Danny Song, Antonio Conde-Moreno, Miguel Angel Berenguer, Bradley Stish, Justine Buroker, Davide Giovanni Bosetti,...
Background Prostate-specific membrane antigen (PSMA) PET is useful in the early detection of oligorecurrent prostate cancer (PCa), but whether PSMA parameters can be used to identify patients who would benefit from metastasis-directed therapy (MDT) with radiation or surgery remains uncertain. Purpose To assess association outcomes PCa after MDT. Materials and Methods In this retrospective analysis a single-center phase II trial that enrolled biochemical recurrence maximal local no evidence...
Abstract Background Tumor hypoxia is associated with prostate cancer (PCa) treatment resistance and poor prognosis. Pimonidazole (PIMO) an investigational probe used in clinical trials. A better understanding of the significance molecular alterations underpinning PIMO-labeled tumor needed for future application. Here, we investigated patients localized PCa, order to apply PIMO as a prognostic tool identify potential biomarkers translation. Methods total 39 PCa were recruited administered...
The University of Toronto - Department Radiation Oncology (UTDRO) has had a well-established Fellowship Program for over 20 years. An assessment its graduates was conducted to evaluate training experience and perceived impact on professional development. Graduates the UTDRO between 1991 2015 were focus our review. Current employment status collected using online tools. A study-specific web-based questionnaire distributed 263/293 whom active e-mails identified; questions focused experience,...
Abstract PURPOSE Neurocognitive dysfunction is common in patients with advanced metastatic cancer. The contribution of brain metastases (BrMets) to neurocognitive outcomes uncertain. We examined the impact BrMets on cognitive before CNS-directed treatment and compared findings cancer without BrMets. Here we present results from an ongoing prospective, longitudinal study. METHODS English-speaking adults followed at lung clinics underwent testing using a standardized battery (prior cranial...
We conducted and previously published a phase 2 trial of metastasis-directed therapy (MDT) in men with recurrence prostate cancer at low prostate-specific antigen level following radical prostatectomy postoperative radiotherapy. All patients had negative conventional imaging underwent membrane (PSMA) positron emission tomography (PET). Patients without visible disease (n = 16) or metastatic not amenable to MDT 19) were excluded from the interventional study. The remaining on PSMA-PET...
Objective: Neurocognitive decline is prevalent in patients with metastatic cancers, attributed to various disease, treatment, and individual factors. Whether the presence of brain metastases (BrMets) contributes neurocognitive unclear. Aims this study are examine performance BrMets compare findings advanced cancer without BrMets. Here, we present baseline from an ongoing, prospective longitudinal study. Participants Methods: English-speaking adults cancers were recruited lung clinics at...
2062 Background: Patients with EGFR mutant non-small cell lung cancer (EGFRmNSCLC) have a high incidence of brain metastases (BM). We sought to determine the rate neurologic death in EGFRmNSCLC patients diagnosed metastases. Methods: A single-institution prospectively managed database identified 204 treated for between 2000 and 2016. estimated actuarial survival rates using Kaplan-Meier method. The (ND) was determined competing risks analysis. ND correlated clinical treatment variables...